Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Ze’ev Ronai receives NCI Outstanding Investigator Award

Ze’ev Ronai, a cancer investigator and director of the Translational Research Institute at Cedars-Sinai, received an Outstanding Investigator Award from NCI.

February 21, 2025

Vol.51 No.07

Clinical Roundup

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science Advances, could improve treatment approaches for this type of cancer.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Thyroid cancer continues to be overdiagnosed, Cedars-Sinai study finds

A study led by Cedars-Sinai investigators provides evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates.

February 07, 2025

Vol.51 No.05

Guest Editorial

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history.

January 17, 2025

Vol.51 No.02

By Dan Theodorescu, Robert A. Figlin, Howard M. Sandler and Joan August

In Brief

John Fryer joins TGen as professor, director of Center for Accelerated Nanotherapeutics

The Translational Genomics Research Institute, part of City of Hope, has announced the appointment of John D. Fryer as a professor in the Division of Bioinnovation and Genome Sciences and director of the newly established Center for Accelerated Nanotherapeutics.

January 17, 2025

Vol.51 No.02

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

YOU MAY BE INTERESTED IN

Ze’ev Ronai receives NCI Outstanding Investigator Award

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

Thyroid cancer continues to be overdiagnosed, Cedars-Sinai study finds

Cedars-Sinai Cancer’s model of care ensured patient care amid wildfires

John Fryer joins TGen as professor, director of Center for Accelerated Nanotherapeutics

Renew today!

Subscriber content

Never miss an issue!

Login